Table 2.

Shedding of Epstein-Barr virus from the oropharynx, and presence of CD20+ B cells in the blood before and after rituximab (RTX) therapy in the second study.

Patient no.	Diagnosis	Treatment	Week of RTX therapy	EBV copies/106 PBMC*	EBV copies/106 throat wash cells	% CD20+ lymphocytes	Total lymphocyte count
6	HIV, DLBCL	EPOCH-R	Pre	590	49,800,000	8.61	1,480
			1	<90	0
			3		0	0.09	1,210
			6		23,800	0	1,650
			7		1,270
			8	<100	0
			11	<80	0
			Post	<110
			Post	<110		3.42	949
7	DLBCL	EPOCH-R	Pre	<70	3	7.19	420
			6	<100	90,300	0.26	1,380
			7		75
			10	<170	2
			13		542	0.12	1,080
			15	<110	0
			Post	<90	8
			Post	<100	396	0.04	835
8	Hodgkin lymphoma	EPOCH-R	Pre	<70	7	7.63	792
			4	<80	1,640	0.23	1,140
			8	<120	94	0.28	138
			10	<170	592	0.74	576
			13		832,000	0.1	662
			Post	<180	1	0.18	477
			Post	<100	55	0.19	220
9	DLBCL	EPOCH-R	Pre	80	16,500	8.66	2,390
			3	<70	4,800	0.17	2,530
			6	<200	4		1,550
			9		410		1,250
			15	<90	77,100	0	929
			Post	<70
			Post	<200	3	0.03	2,010
10	Follicular lymphoma	EPOCH-R	Pre		0
			3	<110	0	0.02	1,550
			6		19	0	1,670
			9	<220	0
			12	<80	0
			Post	<70	4
			Post		119	0	2,340
11	Mantle cell lymphoma	B+EPOCH-R	Pre	20	860	76.39	804
					19,300	58.86	165
					11,600
			3	<90
			4		3,540
			6	<160		68.45	812
			9	<150	234
			12	<100	1,180,000
			13		56,100
			15	<90	43,500
			Post		387,000	42.35	612
			Post	<160	47,000
			Post	270	1,430	12.06	1,530
						0.19	1,210
12	Burkitt lymphoma	EPOCH-R	Pre	950	1,520
			3		0
			6	<130	0
			9	<170	0
			12	<210	0	0.02	3,360
			15	<100	0
			Post	<120	165
			Post	<150	0	5.4	401
13	DLBCL	EPOCH-R	Pre	<110	0	0	627
			3	<90	0
			8	<130	300
			11	<290	0
			14	<140	0
			17	<90	0
			Post	<150
			Post	<180
			Post	0	0	3.1	732
						0	955
14	Mantle cell lymphoma		Pre	280	26,000	0	754
					50,200
			3	<420	13,400
			5	<130	5,520
			7	<210	0
			10	<110	0
			13	<120	0
			Post	<120	0
			Post	<90	0	62.4	966
							1,420
15	Mantle cell lymphoma	B+EPOCH-R	Pre	<80	0
					2,750
					388	10.1	1,130
					199
			3	230	0
			3		0
			6	<60	0
			9	<100	1,370		956
			12	<60	0
			15	<80	0
			Post	0	0		626
			Post	0	0		695
16	Cryoglobulinemia	Rituximab	Pre	<70	0		1,940
			1	<110	37
			2		798
			3	<80	0
			Post		0
17	Burkitt lymphoma	EPOCH-R	Pre	<130	0
			3	<130	0
			5		0
			6	<60
			8	<70	0
			11	<80	0
			Post	0	0
			Post	0	0
			Post	0	0

Abbreviations: DLBCL, diffuse large B-cell lymphoma; EPOCH-R, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; B+EPOCH-R, bortezomib followed by EPOCH-R; HIV, human immunodeficiency virus; RTX, rituximab

^*Values with a “less than” sign were undetectable. The detection limit varied with the patient’s total white blood cell count on that day.